FDA Approves Injectable Lenacapavir as Long-Acting HIV Prevention Option:

The U.S. FDA has approved injectable lenacapavir as a semiannual HIV prevention method. This follows positive outcomes from PURPOSE 1 & 2 clinical trials in 2024. The WHO welcomed the move, highlighting it as a significant step in expanding HIV prevention options with a long-acting, convenient alternative for vulnerable populations.